tricares.comCrawled Oct 26, 2026
TRiCares initiated the TRICURE US IDE pivotal study, the first next-generation Transcatheter Tricuspid Valve Replacement (TTVR) trial to enroll patients in the United States. The company investigates Topaz’s feasibility, safety, and performance in clinical trials.
TR occurs when the tricuspid valve, which regulates the blood flow between the right atrium and right ventricular chamber, fails to close properly. This causes blood to flow backwards into the right atrium.
The Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System is designed to eliminate tricuspid regurgitation through a minimally invasive approach. This system consists of the Topaz Heart Valve Prosthesis and a catheter-based implantation system that flexes with every heartbeat.
Open-heart surgery has been the standard treatment option for repairing or replacing insufficient valves alongside medical treatments. However, with surgical mortality rates ranging from 10% to 35%, the vast majority of TR patients are deemed ineligible for curative surgeries.
Saad, M, Wong, A, El-Hangouche, N. et al. Novel Transcatheter Tricuspid Valve Replacement Device for Recurrent Regurgitation After Failed Surgical Repair. J Am Coll Cardiol Case Rep. 2026, 0 (0). https://doi.org/10.1016/j.jaccas.2026.109755
TRiCares Receives FDA Approval for TRICURE US IDE Pivotal Trial with the Topaz Tricuspid Valve Replacement System
TRiCares Enters into €20 million Loan Agreement with the European Investment Bank
TRiCares develops Topaz, a minimally invasive tricuspid valve replacement system to treat tricuspid regurgitation (TR).
Tricuspid regurgitation (TR) is a serious cardiac condition that occurs when the tricuspid valve, which regulates blood flow between the right atrium and the right ventricle, fails to close properly, causing blood to flow back into the right atrium.
TriCares GmbH collects and processes personal data in line with legal data protection regulations and its privacy policy.
